Inotuzumab ozogamicin (INO), an anti-CD22 antibody conjugated to a calicheamicin payload via a cleavable linker [32], received FDA approval for use as a single agent in patients with R/R B-cell precursor acute lymphoblastic leukemia (ALL), based on the phase III IN-NOVATE trial [32]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.